Cryo-Cell chairman Portnoy buys CCEL shares worth $189,985

David Portnoy, Chairman and Co-CEO of CRYO CELL INTERNATIONAL INC (NASDAQ:CCEL), reported purchasing shares of the company’s common stock in a series of transactions totaling $189,985. The purchases occurred between September 8 and September 10, 2025, with prices ranging from $4.31 to $4.49 per share. These insider purchases come as InvestingPro analysis shows the stock trading near its 52-week low of $4.09, with an analyst target price of $8.50, suggesting significant upside potential.

On September 8, Portnoy acquired 5,271 shares at prices ranging from $4.30 to $4.32. The following day, September 9, he purchased an additional 4,815 shares at prices between $4.48 and $4.49, along with smaller purchases of 185, 156 and 156 shares all at around $4.49. On September 10, Portnoy continued buying, acquiring 11,035 shares at prices ranging from $4.20 to $4.45, 4,817 shares at $4.47, 7,178 shares at prices ranging from $4.20 to $4.45, 7,200 shares at $4.48 and 2,087 shares at $4.48. The company, with a market capitalization of $36 million, offers a notable dividend yield of ~13% and maintains a GOOD financial health score according to InvestingPro metrics.

The purchases were made through various entities, including an IRA, as custodian for his son, by his spouse, by PartnerCommunity, Inc., by uTIPu, Inc. and directly. Following these transactions, Portnoy’s total holdings in CRYO CELL INTERNATIONAL INC common stock include shares held directly, indirectly through a 401K, an LLC (Mayim Limited Partnership), and corporations (PartnerCommunity, Inc. and uTIPu, Inc.). InvestingPro analysis indicates the stock is currently slightly undervalued, with additional ProTips highlighting strong shareholder returns and significant dividend payments.

Portnoy also holds stock options for a significant number of shares at various exercise prices and expiration dates. With the company’s next earnings report due on October 10, 2025, analysts project a return to profitability this fiscal year.

In other recent news, Cryo-Cell International, Inc. has decided to suspend its quarterly cash dividend for the third quarter of fiscal 2025. The company cited lower-than-expected profitability as the reason for this decision. This move reflects Cryo-Cell’s focus on evaluating its financial performance and capital requirements. The company emphasized that future dividend decisions will be influenced by these factors alongside their strategic priorities. Cryo-Cell, known for its role in the cord blood banking industry, made it clear that this decision is part of a broader financial assessment. The company has not provided a specific timeline for when dividends might resume. Investors are advised to consider these recent developments when evaluating Cryo-Cell’s financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.